Skip to content
Study details
Enrolling now

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Obsidian Therapeutics, Inc.
NCT IDNCT06060613ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

52

Study length

about 4.7 years

Ages

18+

Locations

9 sites in CA, FL, KY +4

About this study

This trial is testing the safety and effectiveness of a new treatment called OBX-115 for people with advanced solid tumors. The goal is to see if OBX-115 can help shrink or control cancer growth, while also monitoring how well it's tolerated.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Receive OBX-115
PhasePhase 1/Phase 2
Primary goalThe proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low15%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1

Secondary: Incidence of AEs, The proportion of participants who have a confirmed CR or PR per RECIST v1.1

Body systems

Oncology